证券日报网讯三元生物11月11日在互动平台回答投资者提问时表示，关于"在建工程"的具体构成及金额 变动情况，请查阅公司《2025年半年度报告》中"第八节财务报告""七、合并财务报表项目注 释"之"12、在建工程"部分。 （文章来源：证券日报） ...

证券代码：301206 证券简称：三元生物 公告编号：2025-086 山东三元生物科技股份有限公司 公司于近日收到股东鲁信资本出具的《关于股份减持计划期满暨实施结果的 告知函》，截至本公告日，上述减持计划已期限届满，现将有关情况公告如下： 一、股东股份减持计划实施情况 | 股东 名称 | 减持方式 | | 减持期间 | | | 减持均价 （元/股） | 减持股数 （股） | 减持比例 （%） | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大宗交易 | 2025 -2025 | 年 8 年 10 | 月 月 | 7 日 日 29 | 29.35 | 4,000,000 | 2.000% | | 鲁信 资本 | 集中竞价 | 2025 | 年 8 | 月 | 7 日 | 29.27 | 1,990,050 | | | | | -2025 | 年 10 | 月 | 日 29 | | | 0.995% | | | 合计 | | - | | | - | 5,990,050 | 2.995% | （一）股东减持股份情况 1 / 3 注 1、上 ...

Core Viewpoint - The announcement from San Yuan Bio indicates that shareholder Luxin Capital has completed its share reduction plan, which involved a total reduction of approximately 599,005 shares, representing about 2.995% of the total share capital [1] Summary by Sections Shareholder Reduction Plan - Luxin Capital originally planned to reduce its holdings by up to 6 million shares, or 3% of the total share capital, starting from a specific date in 2025 [1] - As of the announcement date, Luxin Capital executed the reduction between August 7 and October 29, 2025, through block trades and centralized bidding [1] Reduction Details - The total shares reduced included 400,000 shares through block trades and 199,005 shares through centralized bidding, culminating in a total of 599,005 shares [1] - Following the reduction, Luxin Capital's holdings decreased to 193,000 shares, which is 0.97% of the total share capital [1] Impact on Company - The share reduction did not result in a change of control for the company and is not expected to have a significant impact on its operations [1]

Core Viewpoint - San Yuan Bio is a leading enterprise in the global erythritol industry, established in 2007 and listed on the Shenzhen Stock Exchange in 2022, with a focus on the research, production, and sales of erythritol and its compound products [1] Financial Performance - In Q3 2025, San Yuan Bio reported revenue of 476 million yuan, ranking 19th among 24 companies in the industry, while the top company, Meihua Biological, achieved revenue of 18.215 billion yuan [2] - The net profit for the same period was 67.2847 million yuan, also ranking 19th, with the industry leader, Xinhecheng, reporting a net profit of 5.354 billion yuan [2] Financial Ratios - As of Q3 2025, San Yuan Bio's debt-to-asset ratio was 3.73%, significantly lower than the industry average of 28.46%, down from 5.03% year-on-year [3] - The gross profit margin for the same period was 16.15%, an increase from 10.30% year-on-year, but still below the industry average of 28.77% [3] Executive Compensation - The chairman, Nie Zaijian, received a salary of 800,000 yuan in 2024, an increase of 77,200 yuan from the previous year [4] - The general manager, Cheng Baohua, saw his salary rise to 765,000 yuan, up by 102,600 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 3.67% to 15,800, while the average number of circulating A-shares held per account increased by 3.81% to 8,248.95 [5]

Group 1: Industry Overview - The Chinese sugar substitute industry has a competitive hierarchy, with companies having registered capital exceeding 500 million yuan, such as Rhein Biotech, Jinhui Industrial, and Morning Light Biological, while those with capital between 200 million to 500 million yuan include Baolingbao and Bailong Chuangyuan [1] - The primary production regions for sugar substitute companies in China are Shandong, Hebei, and Anhui provinces, with Shandong housing the most companies, including Sanyuan Biological, Baolingbao, and Bailong Chuangyuan [1] Group 2: Revenue Rankings - In 2024, Huakang Co., Ltd. leads the revenue ranking among listed sugar substitute companies in China, with sales exceeding 1.9 billion yuan. Baolingbao, Rhein Biotech, and Sanyuan Biological follow, each with revenues exceeding 500 million yuan [5] Group 3: Industry Concentration - The concentration levels in the sugar substitute industry are high for products like sucralose, aspartame, and sugar alcohols. Major manufacturers of sucralose include Jinhui Industrial and Shandong Kangbao, while aspartame is primarily produced by companies like Hanguang Sweeteners and the Vito Company [8] Group 4: Company Layout - Companies like Sanyuan Biological and Huakang Co., Ltd. have a high proportion of their business in sugar substitutes. Many companies focus on sugar alcohol products, with Huakang Co., Ltd. producing over 170,000 tons of crystalline sugar alcohol [9][11] - Key sales markets for Chinese sugar substitute companies include China, the Americas, Europe, and Japan and South Korea [9] Group 5: Competitive Analysis - The competitive state of the sugar substitute industry in China shows moderate competition among existing firms, with a significant threat from potential new entrants due to growing health demands [12] - The bargaining power of upstream suppliers is strong, as the main raw materials are sourced from starch and chemical raw material companies, which are generally larger than the sugar substitute manufacturers [12] - The bargaining power of downstream customers is relatively weak, especially for small clients, while industry leaders maintain some pricing power [12]

Computing - Chuangwei Data reports strong market demand for cloud computing services, with high server rental rates [1] Semiconductor - Tengjing Technology indicates a robust order backlog in the semiconductor equipment sector [1] - Zhongdian Port states that the revenue contribution from the agency of Nexperia semiconductor product line is relatively small [1] - Tianzhun Technology mentions that Suzhou Xihang Semiconductor's inline inspection equipment can be used for quality control in memory chip manufacturing [1] - Glinda has begun mass production of photoresist for semiconductors, supplying leading companies [1] Quantum Technology - Tefa Information currently has no involvement in the quantum technology sector [1] Robotics - Hengfeng Tools has provided tool trial services to over ten humanoid robot component manufacturers [1] Solid-State Batteries - Funeng Technology is steadily constructing its pilot line for solid-state batteries [1] Commercial Aerospace - Zhongji Renjian has not yet initiated any commercial aerospace business [1] Other - Shenling Environment's products are serving a compact fusion energy experimental device project [1] - Shanda Electric Power currently has no business related to controllable nuclear fusion [1] - Sanyuan Bio's intelligent biomass energy project has been terminated due to approval delays [1]

Core Viewpoint - San Yuan Bio (301206) has decided to terminate its planned investment in an intelligent biomass energy project due to approval obstacles [1] Company Summary - The company had initially intended to invest in a smart biomass energy project [1] - The decision to halt the project was made recently following difficulties in obtaining necessary approvals [1]

证券代码：301206 证券简称：三元生物 公告编号：2025-085 山东三元生物科技股份有限公司 关于使用暂时闲置超募资金进行现金管理的进展公告 近日，公司使用暂时闲置超募资金在授权范围内购买了理财产品，现将具体 情况公告如下： | 序 | | | 产品 | | | 认购金额 | 实际年化 | 收益金额 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 发行主体 | 产品名称 | 类型 | 起始日期 | 到期日期 | （万元） | 收益率 | （万元） | | | | 2025 年挂钩 | | | | | | | | | 中国光大 | 汇率对公结 | | | | | | | | | 银行股份 | | 保本浮 | | | | | | | 1 | | 构性存款定 | | 2025/09/24 | 2025/10/24 | 2,300.00 | 1.65% | 3.16 | | | 有限公司 | | 动收益 | | | | | | | | | 期第九期产 | | | | | | | | | 滨州分行 | | | | | | | | | ...

Group 1 - The core viewpoint of the article highlights that San Yuan Bio (301206.SZ) reported its Q3 2025 financial results, showing a revenue increase but a significant decline in net profit [1] Group 2 - In Q3, the company achieved an operating income of 158 million yuan, representing a year-on-year growth of 14.51% [1] - The net profit for Q3 was 9.92 million yuan, which reflects a year-on-year decrease of 65.91% [1] - For the first three quarters, the company reported a total operating income of 476 million yuan, down 7.54% year-on-year [1] - The net profit for the first three quarters was 81.01 million yuan, showing a year-on-year decline of 16.80% [1]

Core Viewpoint - Shandong Sanyuan Biotechnology Co., Ltd. has decided to terminate its planned investment of 200 million yuan in an intelligent biomass energy project due to obstacles in obtaining necessary approvals, which has prevented the project from commencing construction [1][3]. Project Overview - The intelligent biomass energy project was initially approved by the company's fourth board meeting on July 22, 2022, with a planned investment of 200 million yuan using self-owned funds. The project's core objective was to reduce production costs in line with the company's strategic development needs [2]. Reasons for Termination - The company faced significant delays in the approval process, stating that it has not received the necessary approvals from relevant authorities, which has hindered the project's progress. After a comprehensive evaluation, the company concluded that the project could not be pursued as originally planned and decided to terminate it based on prudence [3]. Impact on the Company - The termination of the project will not have a significant impact on the company's operations or financial status, as the project had not yet commenced construction. The decision was made after considering changes in the policy environment and approval regulations, ensuring that normal operations remain unaffected. The company will continue to focus on its core business in the fermentation sector, which includes products like erythritol [4]. Market analysts noted that since no substantial funds had been invested, the termination would have limited short-term effects on the company's performance and cash flow [4].